Original articleSerum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events
Abbreviations and Acronyms
Cited by (0)
Supplemental material available at www.ophthalmologyretina.org.
Financial Disclosure(s):
Funding: The IVAN trial is funded by the UK National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme (project number 07/36/01). The views and opinions expressed are those of the authors and do not necessarily reflect those of the HTA programme, the NIHR, the UK National Health Service, or the Department of Health.
Conflicts of Interest: C.A.R.: Lecture honorarium — Novartis. B.C.R.: Teaching fee — Janssen-Cilag. S.D.: Lecture honoraria — Novartis; her employing institution has received payments from Novartis. A.J.L.: Chief investigator — trial investigating treatment of chorioretinopathy; Is principal investigator — trials sponsored by Novartis, the manufacturers of ranibizumab; Advisory boards — Novartis and Bayer. U.C.: Principal investigator — trials sponsored by Novartis; advisory boards — Novartis, Bayer, and Roche outside the submitted work; employing institution has received payments — Novartis, Bayer, Neovista, Oraya, and Alcon.
Author Contributions:
Research design: Rogers, Scott, Reeves, Chakravarthy
Data acquisition and/or research execution: Downes, Lotery, Dick, Chakravarthy
Data analysis and/or interpretation: Rogers, Scott, Reeves
Manuscript preparation: Rogers, Scott, Reeves, Downes, Lotery, Dick, Chakravarthy
Human Subjects: This study includes human subject/tissues. Participants gave written informed consent for collection and analysis of serum samples in the IVAN trial, which was approved by a UK NHS Research Ethics Committee (reference: 07/NIR03/37).